$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
美国礼来制药的雷莫芦单抗需要用多久?
2025-10-19 11:44:20
Check Details
ctDNA可预测I - III期结直肠癌术后疾病复发风险
2025-10-19 11:44:20
Check Details
人工智能有助于识别早发性结直肠癌的新危险因素
2025-10-19 11:44:20
Check Details
碧康瑞格非尼价格
2025-10-19 11:44:20
Check Details
碧康瑞格非尼效果怎么样?
2025-10-19 11:44:20
Check Details
瑞格非尼适用于什么病症?
2025-10-19 11:44:20
Check Details
礼来制药的雷莫芦单抗安全性怎么样?
2025-10-19 11:44:20
Check Details
高危II期结直肠癌辅助双重化疗:3个月还是6个月?
2025-10-19 11:44:20
Check Details
瑞格非尼购买途径
2025-10-19 11:44:20
Check Details
碧康瑞格非尼的价格
2025-10-19 11:44:20
Check Details
碧康瑞格非尼多少粒一盒?
2025-10-19 11:44:20
Check Details
瑞格非尼靠谱吗?
2025-10-19 11:44:20
Check Details
1
2
...
1614
1615
1616
1617
1618
1619
1620
...
4157
4158
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Tivozanib: A Next-Generation Highly Selective VEGFR-Targeted Therapy Explained
2
Capmatinib Clinical Guide: Drug Comparisons, Treatment Strategies, and Combination Therapy Prospects
3
Pralsetinib Clinical Guide: Discontinuation Principles, Drug Comparisons, and Treatment Strategies
4
Dabrafenib Clinical Guide: Indications, Combination Strategies, and BRAF Inhibitor Comparisons
5
Cabozantinib Capsules: A Multi-Targeted Therapy for Progressive Medullary Thyroid Cancer
6
Lorlatinib: Mechanism, Advantages, and Key Considerations of Third-Generation ALK Inhibitor Therapy in ALK-Positive NSCLC
7
Pemigatinib Side Effects Explained: Managing Adverse Reactions of FGFR-Targeted Therapy in Cholangiocarcinoma
8
Selpercatinib: Before or After Meals? A Complete Guide to RET-Targeted Therapy Administration
9
Mitotane for Adrenocortical Carcinoma: Dosing Guidelines and Therapeutic Drug Monitoring
10
Leflunomide and Ocular Adverse Effects: Risk Awareness and Clinical Guidance
11
Clinical Management of Acquired Resistance to Garsorasib (KRAS G12C Inhibitor)
12
Chemical Structure of Capivasertib: A Novel AKT Inhibitor